破解免疫疗法起效之谜。
Solving the puzzle of what makes immunotherapies work.
机构信息
Center for Immunotherapy and Precision Immuno-Oncology, Cleveland Clinic, Cleveland, OH 44195, USA.
Center for Immunotherapy and Precision Immuno-Oncology, Cleveland Clinic, Cleveland, OH 44195, USA; Case Western School of Medicine, Cleveland, OH 44106, USA.
出版信息
Trends Cancer. 2022 Nov;8(11):890-900. doi: 10.1016/j.trecan.2022.06.011. Epub 2022 Aug 3.
Abstract
The rapid adoption of immune checkpoint blockade (ICB) therapies has led to a need to understand the mechanistic drivers of efficacy and the identification of novel biomarkers that enrich for patients who benefit from ICB therapy. Here, we provide a perspective on emerging biomarker candidates, their underlying biological mechanisms, and how they may fit into the current landscape of ICB biomarkers. We discuss new frameworks to identify and evaluate biomarker candidates and review the opportunities and challenges of utilizing biomarker-derived models to facilitate the development of new immunotherapies.
摘要
免疫检查点阻断 (ICB) 治疗的快速采用导致人们需要了解疗效的机制驱动因素，并确定新的生物标志物，以富集从 ICB 治疗中受益的患者。在这里，我们提供了对新兴生物标志物候选物的观点，它们的潜在生物学机制，以及它们如何适应当前的 ICB 生物标志物格局。我们讨论了识别和评估生物标志物候选物的新框架，并回顾了利用生物标志物衍生模型促进新免疫疗法发展的机会和挑战。
相似文献
1
Solving the puzzle of what makes immunotherapies work.
Trends Cancer. 2022 Nov;8(11):890-900. doi: 10.1016/j.trecan.2022.06.011. Epub 2022 Aug 3.
2
Mechanisms of tumor resistance to immune checkpoint blockade and combination strategies to overcome resistance.
Front Immunol. 2022 Sep 15;13:915094. doi: 10.3389/fimmu.2022.915094. eCollection 2022.
3
Biomarkers of Immune Checkpoint Blockade Response in Triple-Negative Breast Cancer.
Curr Treat Options Oncol. 2021 Mar 20;22(5):38. doi: 10.1007/s11864-021-00833-4.
4
Factors Determining Long-Term Antitumor Responses to Immune Checkpoint Blockade Therapy in Melanoma.
Front Immunol. 2022 Jan 11;12:810388. doi: 10.3389/fimmu.2021.810388. eCollection 2021.
5
Combinational Immunotherapy for Hepatocellular Carcinoma: Radiotherapy, Immune Checkpoint Blockade and Beyond.
Front Immunol. 2020 Sep 30;11:568759. doi: 10.3389/fimmu.2020.568759. eCollection 2020.
6
Combination immunotherapy strategies for glioblastoma.
J Neurooncol. 2021 Feb;151(3):375-391. doi: 10.1007/s11060-020-03481-0. Epub 2021 Feb 21.
7
Immune checkpoint blockade in glioblastoma: from tumor heterogeneity to personalized treatment.
J Clin Invest. 2023 Jan 17;133(2):e163447. doi: 10.1172/JCI163447.
8
The current landscape of predictive and prognostic biomarkers for immune checkpoint blockade in ovarian cancer.
Front Immunol. 2022 Oct 27;13:1045957. doi: 10.3389/fimmu.2022.1045957. eCollection 2022.
9
Therapeutically Increasing MHC-I Expression Potentiates Immune Checkpoint Blockade.
Cancer Discov. 2021 Jun;11(6):1524-1541. doi: 10.1158/2159-8290.CD-20-0812. Epub 2021 Feb 15.
10
It takes two to tango: the role of tumor-associated macrophages in T cell-directed immune checkpoint blockade therapy.
Front Immunol. 2023 Jun 9;14:1183578. doi: 10.3389/fimmu.2023.1183578. eCollection 2023.
引用本文的文献
1
CSTF2-impeded innate αβ T cell infiltration and activation exacerbate immune evasion of pancreatic cancer.
Cell Death Differ. 2025 May;32(5):973-988. doi: 10.1038/s41418-025-01464-0. Epub 2025 Feb 19.
2
Establishing a model composed of immune-related gene-modules to predict tumor immunotherapy response.
Sci Rep. 2024 Jul 18;14(1):16630. doi: 10.1038/s41598-024-67742-y.
3
Machine learning-based extrachromosomal DNA identification in large-scale cohorts reveals its clinical implications in cancer.
Nat Commun. 2024 Feb 19;15(1):1515. doi: 10.1038/s41467-024-45479-6.
4
Sequential Chromogenic IHC: Spatial Analysis of Lymph Nodes Identifies Contact Interactions between Plasmacytoid Dendritic Cells and Plasmablasts.
Cancer Res Commun. 2023 Jul 13;3(7):1237-1247. doi: 10.1158/2767-9764.CRC-23-0102. eCollection 2023 Jul.
5
New frontiers in immune checkpoint B7-H3 (CD276) research and drug development.
Mol Cancer. 2023 Mar 2;22(1):43. doi: 10.1186/s12943-023-01751-9.
6
Decoding Roles of Exosomal lncRNAs in Tumor-Immune Regulation and Therapeutic Potential.
Cancers (Basel). 2022 Dec 31;15(1):286. doi: 10.3390/cancers15010286.
本文引用的文献
1
Computational cancer neoantigen prediction: current status and recent advances.
Immunooncol Technol. 2021 Nov 20;12:100052. doi: 10.1016/j.iotech.2021.100052. eCollection 2021 Dec.
2
Cancer Neoantigens: Challenges and Future Directions for Prediction, Prioritization, and Validation.
Front Oncol. 2022 Mar 3;12:836821. doi: 10.3389/fonc.2022.836821. eCollection 2022.
3
Discordance in Tumor Mutation Burden from Blood and Tissue Affects Association with Response to Immune Checkpoint Inhibition in Real-World Settings.
Oncologist. 2022 Mar 11;27(3):175-182. doi: 10.1093/oncolo/oyab064.
4
Artificial Intelligence-Powered Spatial Analysis of Tumor-Infiltrating Lymphocytes as Complementary Biomarker for Immune Checkpoint Inhibition in Non-Small-Cell Lung Cancer.
J Clin Oncol. 2022 Jun 10;40(17):1916-1928. doi: 10.1200/JCO.21.02010. Epub 2022 Mar 10.
5
Intestinal microbiota signatures of clinical response and immune-related adverse events in melanoma patients treated with anti-PD-1.
Nat Med. 2022 Mar;28(3):545-556. doi: 10.1038/s41591-022-01698-2. Epub 2022 Feb 28.
6
Outcomes Among Patients With or Without Obesity and With Cancer Following Treatment With Immune Checkpoint Blockade.
JAMA Netw Open. 2022 Feb 1;5(2):e220448. doi: 10.1001/jamanetworkopen.2022.0448.
7
Acquired resistance to anti-MAPK targeted therapy confers an immune-evasive tumor microenvironment and cross-resistance to immunotherapy in melanoma.
Nat Cancer. 2021 Jul;2(7):693-708. doi: 10.1038/s43018-021-00221-9. Epub 2021 Jul 15.
8
Mutational landscape influences immunotherapy outcomes among patients with non-small-cell lung cancer with human leukocyte antigen supertype B44.
Nat Cancer. 2020 Dec;1(12):1167-1175. doi: 10.1038/s43018-020-00140-1. Epub 2020 Nov 16.
9
HLA-A*03 and response to immune checkpoint blockade in cancer: an epidemiological biomarker study.
Lancet Oncol. 2022 Jan;23(1):172-184. doi: 10.1016/S1470-2045(21)00582-9. Epub 2021 Dec 9.
10
Extrachromosomal DNA: An Emerging Hallmark in Human Cancer.
Annu Rev Pathol. 2022 Jan 24;17:367-386. doi: 10.1146/annurev-pathmechdis-051821-114223. Epub 2021 Nov 9.
Zotero 插件